Keith Ward
Sep 9
Kuria Therapeutics Awarded NIH Grant to Advance SCO-116 for Fuchs’ Endothelial Corneal Dystrophy
Kuria awarded a Phase I NIH SBIR grant to advance SCO-116 for Fuchs' dystrophy
top of page
Search
Keith Ward
Mar 5
Kuria Therapeutics Advances NIH-Funded SBIR Efforts for Lead Ophthalmology Program
Kuria announces that its NIH SBIR grant has received matching funds from the Arkansas Economic Development Commission. Funds will amplify the impact of the federal research dollars.
Keith Ward
Sep 11, 2025
Kuria Therapeutics Awarded NIH/NEI SBIR Fast Track Phase I/II Grant to Advance IND-Enabling Toxicology Studies of SCO-116 for Corneal Endothelial Disease and Injury
Kuria granted an SBIR award to fund IND-enabling toxicology studies for Fuchs' dystrophy.
Keith Ward
Sep 8, 2022
Seed Round Completed
Kuria Therapeutics Closes Initial Fundraising Round to Develop Novel Nrf2 Activator - Funds to support ongoing preclinical development...
bottom of page